10x Genomics director John Stuelpnagel sells $1.15m in shares

John R. Stuelpnagel, a director at 10x Genomics, sold 20,000 shares of the company's Class A Common Stock, amounting to $1,155,055, on August 11, 2026. The shares were sold at prices between $57.5812 and $58.725 per share. One transaction involved the sale of 17,000 shares at a weighted average price of $57.5812. Additionally, 3,000 shares were sold at $58.725.

This sale occurred as TXG stock approaches its 52-week high of $60.69, following a significant 339% increase over the past year. Currently, the stock has a market capitalization of $7.58 billion. Post-transactions, Stuelpnagel retains 348,436 shares of 10x Genomics Class A Common Stock. According to InvestingPro analysis, the stock is currently overvalued compared to its Fair Value.

Investors can access further insights through 15 ProTips and in-depth financial metrics. In related news, 10x Genomics reported stronger-than-expected second-quarter 2026 results, with revenue of $151.04 million and an adjusted loss per share of $0.14. Despite this, the stock declined as investors weighed the company's more cautious outlook and its shift to the Atera platform. Canaccord raised its price target for 10x Genomics to $60, signaling a 15% potential upside.